2025年4月25日至30日，美国癌症研究协会 (AACR)年会于芝加哥召开。基石药业 (02616) 5款自主研发创新药物的最新临床前研究成果 将同时亮相这一国际顶级学术舞台，包括三抗CS2009、双抗CS2011及出自公司自有抗体偶联药物 (ADC)平台的三款创新ADC分子CS5006、CS5007与CS5005。相关研究摘要将于美国东部时间4月11日发表于AACR官方期刊《Cancer ...

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

"Anti-GPRC5D CAR T-cell salvage therapy induced a high response rate and might be a potential treatment option in patients with relapsed or refractory multiple myeloma who had pro ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

The company has 51 applications pending at various stages in the approval process. ETMarkets.com ISB 2001, a trispecific antibody, which aims to treat multiple myeloma, a type of blood cancer, may ...

Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease ...

Trispecific antibodies and combination therapies are also being studied to improve tumor specificity or immune-cell activation. Chimeric antigen receptor (CAR) T-cell therapies are another area of ...

Merge Therapeutics, based in MBC BioLabs, San Carlos, CA, is developing trispecific antibodies for deep depletion of pathogenic cells in autoimmune disease. PHAME, based in BioLabs, Heidelberg ...

今日（3月26日），基石药业宣布，其5款自主研发创新药物的最新临床前研究成果将同时亮相2025年美国癌症研究协会（AACR）年会，包括 三抗 CS2009、 双抗 CS2011及 三款创新抗体偶联药物（ADC） CS5006、CS5007与CS5005。相关研究摘要将于美国东部时间4月11日发表于AACR官方期刊 Cancer Research。